The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.

NICE commissioned an external assessment centre (EAC) to review the evidence submitted by the company. This section summarises that review. Full details of all the evidence are in the project ...

Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) - Additional studies examine ...

In a ground-breaking medical achievement, Nigeria has become the first country in West and Central Africa to successfully perform the UroLift procedure, a revolutionary treatment for benign prostate ...

Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...

As the population ages, the prevalence of Benign Prostatic Hyperplasia (BPH)—commonly known as an enlarged prostate—has increased significantly. Over 50% of men over 60 and 80% of those over 70 ...

Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...

Nigeria may soon become a medical tourism destination of choice for prostate treatment, following a historic medical breakthrough at The Prostate Clinic, TPC, in Lagos, where a team led by Professor ...